Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28005008 | 0.86 | TDP1 (0.53) | TDP1MAP2K1ALDH1A1MAPTHTT | |
| SCHEMBL28006174 | 0.86 | TDP1 (0.53) | TDP1MAP2K1ALDH1A1MAPTHTT | |
| SCHEMBL28027851 | 0.86 | TDP1 (0.53) | TDP1MAP2K1KDM4EALDH1A1MAPT | |
| SCHEMBL949562 | 0.85 | TDP1 (0.50) | TDP1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL31081770 | 0.83 | TDP1 (0.49) | TDP1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL30592857 | 0.83 | TDP1 (0.57) | TDP1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL18201 | 0.83 | TDP1 (0.57) | TDP1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL8427582 | 0.83 | TDP1 (0.49) | TDP1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL15662188 | 0.83 | TDP1 (0.61) | TDP1MAP2K1KDM4EALDH1A1MAPT | |
| SCHEMBL311599 | 0.83 | L3MBTL1 (0.59) | ALDH1A1MAPTHTTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-113649055-B | Catalyst for selective hydrogenation of methyl picolinate and preparation method and application thereof | 湖北大学 | 2023-03-24 | — | — | CN | claimed |
| CN-113649055-A | Catalyst for selective hydrogenation of methyl picolinate and preparation method and application thereof | 湖北大学 | 2021-11-16 | — | — | CN | claimed |
| CN-121673214-A | Synthetic method of isoindolone | 南京工业大学 | 2026-03-17 | — | — | CN | disclosed |
| CN-121378099-A | Application of isoindolone compound | 南京工业大学 | 2026-01-23 | — | — | CN | disclosed |
| WO-2025110780-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS DNA POLYMERASE THETA INHIBITORS FOR THE PREVENTION OR TREATMENT OF CANCER | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-05-30 | — | — | WO | disclosed |
| CN-120040437-A | Novel heterocyclic compound and pharmaceutical composition comprising same | 株式会社大熊制药 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025087375-A1 | NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE AGONIST AND USE THEREOF | 南京瑞初医药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| US-12234220-B2 | Immunomodulatory compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-114026081-B | Pyridone derivatives as selective cytotoxic agents against HIV-infected cells | 默沙东有限责任公司 | 2025-02-11 | — | — | CN | disclosed |
| US-4980357-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1990-12-25 | — | — | US | disclosed |
| US-4812471-A | Hypoglycemic 5-(isoxazolyl or isothiazolyl)-oxazolidine-2,4-diones | PFIZER INC. (US) | 1989-03-14 | — | — | US | disclosed |
| WO-1989001775-A1 | AZOLIDINEDIONE DERIVATIVES | PFIZER INC. (US) | 1989-03-09 | — | — | WO | disclosed |
| EP-0306251-A2 | Azolidinedione derivatives | PFIZER INC. (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4753956-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4689336-A | Hypoglycemic 5-substituted oxazolidine 2,4-diones | PFIZER INC. (US) | 1987-08-25 | — | — | US | disclosed |
| US-4565820-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4431810-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4342771-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234220-B2 | Immunomodulatory compounds | CRBN, CD47, CD58 | TDP1 1998/4885MAP2K1 4846/4885KDM4E 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.